Background {#Sec1}
==========

Chronic hepatitis C infection is a global healthcare burden and associated with the development of liver cirrhosis, hepatocellular carcinoma, and death if untreated \[[@CR1]\]. In China, the prevalence of HCV in the general population is estimated as 1.6% \[[@CR2], [@CR3]\], which equals to approximately 20 million HCV carriers. A minority of acutely infected individuals (approximately 15--40%) will resolve their infection and recover spontaneously \[[@CR4]\]. It is reported that among host factors, gender, age, *IFNL3* (previously *IL28B*) genotypes, *KIR/HLA* alleles, ethnicity, and HIV co-infection are associated with spontaneous recovery \[[@CR5]--[@CR15]\]. In particular, female sex and favorable *IFNL3* genotypes (rs12979860 CC, rs8099917 TT and rs12980275 AA) are primary independent predictors of spontaneous clearance \[[@CR5]--[@CR9], [@CR12], [@CR13], [@CR16], [@CR17]\]. In the general Han Chinese ethnic population, the three favorable *IFNL3* genotypes are very common (\~ 90%) \[[@CR12], [@CR16]--[@CR18]\]. However, many females carrying favorable *IFNL3* genotypes suffer from chronic hepatitis C in China, indicating that besides *IFNL3* genotypes and possibly some *KIR/HLA* alleles, other immune-related factors associated with HCV spontaneous clearance still remain unknown.

T helper 17 cells (Th17), a subset of pro-inflammatory T helper cells, play an important role in adaptive immunity, protecting hosts against pathogens primarily through secreting cytokines(such as IL-17A, IL-17F, IL-21, and IL-22) \[[@CR19]\]. Receptor retinoic acid-related orphan receptor C (RORC), a DNA-binding transcription factor, is the master regulator of Th17 differentiation \[[@CR20], [@CR21]\]. Th17 cells may have dual roles (both harmful and beneficial) in HCV-related disease \[[@CR22]\]. Specific HCV-Th17 cells are involved in immune response modulation, and their levels are associated with severity of fibrosis and intrahepatic inflammatory status \[[@CR23], [@CR24]\]. On the other hand, several reports indicate that elevated Th17 responses could be associated with spontaneous HCV clearance \[[@CR25], [@CR26]\].

In this study, two single nucleotide polymorphisms (SNPs) located in the *RORC* gene were identified to be associated with spontaneous clearance of HCV infection.

Methods {#Sec2}
=======

Participants {#Sec3}
------------

In the present study, 190 HBsAg-negative, anti-HCV-positive, Han Chinese females were identified by screening a total of 1252 residents (80% of the local population) in Wangying Village, Shangcai County, Henan province, in August 2009. More than 90% of patients were former plasma donors, and the remaining individuals composed of their parents, spouses, or children. Samples were tested for anti-HCV antibody using the Architech anti-HCV system (Abbott Diagnostics, USA), and those with signal/cut-off ratios between 1.0 and 5.0 were confirmed by RIBA assay (HCV BLOT 3.0, MP diagnostics, USA). Plasma HCV viral load was determined using the Abbott RealTime HCV Amplification Kit (Abbott Molecular Inc., USA) according to the manufacturer's instructions. Spontaneous resolvers were defined as subjects who were positive for HCV antibody and negative for plasma HCV RNA with no history of HCV-specific treatment. HCV RNA-negative status was confirmed in a second sample collected in 2012 and/or 2013. Chronic HCV carriers were defined as those patients positive for both HCV antibody and plasma HCV viral load and also confirmed by the follow-up detection. No participants had received any type of HCV-specific antiviral therapy. All subjects were screened for HIV-1 infection status. Anti-HIV-1 antibody status was initially tested by ELISA assay (GBI biotech Co., Ltd., Beijing, China) and confirmed by HIV Blot 2.2 WB assay (Genelabs Diagnostics, Singapore). All HIV-positive patients had received first-line antiretroviral therapy for 6\~ 8 years, regularly or intermittently. None of the participants received any types of anti-HCV treatment.

Of 190 female anti-HCV-positive individuals, HIV^pos^ women with chronic HCV infection (*n* = 53) were excluded from the study, as HIV infection could affect the ability of some individuals to spontaneously resolve their HCV infection. The final case number of primary cohort was 137, which consisted of a "Chronic" group (HIV^neg^ HCV carriers, *n* = 64) and a "Resolved" group (*n* = 73, including 45 HIV^neg^ HCV resolvers and 28 HIV^pos^ HCV resolvers). Overall, the cohort exhibited a similar high frequency of *IFNL3* favorable genotypes to Han Chinese nationality (Additional file [1](#MOESM1){ref-type="media"}: Table S1), indicating that the study was based on a representative cohort of the Chinese population \[[@CR12], [@CR16]\]. To eliminate the influence of *IFNL3* SNPs on viral clearance, a sub-cohort carrying favorable *IFNL3* genotypes (rs12979860CC, rs8099917TT, rs12980275 AA) was constructed and analyzed. The *IFNL3* favorable sub-cohort included 54 and 67 participants in the "Chronic" and "Resolved" (HIV^neg^, *n* = 43; HIV^pos^, *n* = 24) groups, respectively. A flow diagram for cohort construction was provided as Fig [1](#Fig1){ref-type="fig"}. The clinical and biochemical characteristics of the primary cohort were presented in Table [1](#Tab1){ref-type="table"}.Fig. 1Flow diagram of study cohort selection. From a total of 1252 residents of Wangying Village, Shangcai County, 190 anti-HCV-positive female Chinese Han individuals were initially recruited to the study after screening. Of these 190 subjects, 53 HIV-positive women with chronic HCV infections were excluded. The remaining 137 females constituted the primary cohort, which consisted of "Chronic" (HIV- HCV carriers, *n* = 64) and "Resolved" (total *n* = 73: HIV+ HCV resolvers, *n* = 28, and HIV- HCV resolvers, *n* = 45) groups. An *IFNL3* favorable sub-cohort was also constructed by exclusion of women with unfavorable *IFNL3* genotypes (rs12979860 TC/TT, rs80999917 TG/TT, and rs12980275AG/GG; "Chronic", *n* = 54, and "Resolved", *n* = 67)Table 1Characteristics of individuals in the primary cohortCharacteristicChronic HCV (*n* = 64)Resolved HCV (n = 73)HIV^neg^ (*n* = 45)HIV^pos^ (*n* = 28)Age (years)^a^50 (47--59)59 (49--67)54 (47--64)BMI^a^23.5 (21.1--26.1)23.2 (21.3--26.3)22.1 (20.5--24.5)Anti-HCVPositivePositivePositiveAnti-HIVNegativeNegativePositiveHCV RNA (log~10~ IU/mL)^a^6.17 (5.82--6.54)NegativeNegativeHCV genotype 1b (n,%)^b^39 (60.9%)---- 2a (n,%)^b^25 (39.1%)---- OthersNone----ALT (n,%) \> 40 (IU/L)^b^28 (43.7%)4 (8.9%)7 (25.0%) ≤40 (IU/L)^b^36 (56.3%)41 (91.1%)21 (75.0%)AST (n,%) \> 40 (IU/L)^b^30 (46.9%)1 (2.2%)7 (25.0%) ≤40 (IU/L)^b^34 (53.1%)44 (97.8%)21 (75.0%) CD4+ T cells/μL^a^882 (599--1088)888 (658--1119)445 (346--587)Data presented as ^a^medians (inter-quartile range) or ^b^number of cases (%)*BMI* body mass index, *ALT* alanine aminotransferase, *AST* aspartate aminotransferase

SNP selection and genotyping {#Sec4}
----------------------------

A total of 111 SNPs in 23 genes encoding HCV co-receptors (*CD81*, *SCARB1*, *CLDN1*, *OCLN*, *NPC1L1*, *APOE*, *LDLR*), transcription factors(*IRF3*, *RORC*, *TBX21*, *FOXP3*, *BCL6*), Toll-like receptors (*TLR3*, *TLR7*, *TLR9*), co-stimulating molecules (*ICOS*, *CXCR5*, *CD40LG*), and cytokines(*IL4*, *IFNG*, *IL21*, *IFNL3*, *CXCL13*) were selected for SNP analysis (Additional file [1](#MOESM1){ref-type="media"}: Table S2). The selected SNPs met at least one of the following criteria:1) a reported minor allele frequency \> 10% in the Han Chinese population according to SNP browser software 4.0 (Applied Biosystems), with reference to the NCBI SNP database (<http://www.ncbi.nlm.nih.gov/projects/SNP/>); 2) published evidence that the SNP was associated with disease.

Genomic DNA extracted from whole blood samples using a DNeasy Blood & Tissue kit (Qiagen, USA) was dissolved in sterile double distilled water and stored at − 20 °C until use. DNA purity was checked and DNA samples with 260/280 ratios\< 1.7 were re-purified. SNP genotyping was performed using the iPLEX Sequenom MassARRAY system (Sequenom Inc., USA).

Statistical analyses {#Sec5}
--------------------

Statistical and graphical analyses were performed using GraphPad Prism 5.0, Microsoft Excel 2007, or SPSS 20.0. The allele frequency and genotype distributions of each SNP were descriptively summarized as numbers of cases and frequencies. Chi-square (χ^2^) and Fisher's exact tests were used to examine differences in frequencies of individual SNPs between HCV carriers and spontaneous resolvers. SNP-specific deviation from Hardy--Weinberg Equilibrium (HWE) in the whole study population was tested using a χ^2^ test in SHEsis software, and SNPs with HWE violation (*P* \< 0.01) were excluded. Pairwise D′ and r^2^ measures of linkage disequilibrium for *RORC* SNPs were calculated using SHEsis (<http://analysis.bio-x.cn/myAnalysis.php>). Specific parameters were set as previously described \[[@CR27]\]. *P*-values, odds ratios (ORs), and 95% confidence intervals (95% CIs) were used for association analysis. All *P*-values were two-tailed, and were considered significant at \< 0.05.

Results {#Sec6}
=======

Associations between target gene SNPs and spontaneous HCV clearance in the primary cohort {#Sec7}
-----------------------------------------------------------------------------------------

Genotype distributions and allele frequencies were calculated for 111 candidate SNPs in both the "Chronic" and "Resolved" groups of the primary cohort (Additional file [1](#MOESM1){ref-type="media"}: Table S2). The frequencies of favorable *IFNL3* genotypes were higher in "Resolved" group than "Chronic" group (resolved vs. chronic: rs12979860, CC 96% vs. 86%; rs8099917, TT 95% vs. 91%; and rs12980275, AA 96% vs. 86%), although only the difference in the frequency of the rs12979860 C allele was statistically significant (*P* = 0.043) (Table [2](#Tab2){ref-type="table"}).Table 2Genotype and allele frequency distributions of *IFNL3*and *RORC*SNPs in the primary cohortSNPGenotypeChronic HCV^a^(*n* = 64)Resolved HCV^a^(*n* = 73)*P*-valueOR (95% CI)rs12979860CC55 (0.85)70(0.96)0.105TT1 (0.02)0 (0.00)CT8 (0.13)3 (0.04)C allele118 (0.92)143 (0.98)**0.043**0.25 (0.07--0.87)T allele10 (0.08)3 (0.02)4.04 (1.15--13.89)rs8099917TT58(0.91)69 (0.95)0.514GG0 (0.00)0 (0.00)GT6 (0.09)4 (0.05)T allele122 (0.95)142 (0.97)0.5230.57 (0.16--2.08)G allele6 (0.05)4 (0.03)1.75 (0.48--6.33)rs12980275AA55 (0.85)69 (0.96)0.189GG1 (0.02)0 (0.00)AG8 (0.13)4 (0.04)A allele118 (0.92)142 (0.97)0.0960.33 (0.10--1.09)G allele10 (0.08)4 (0.03)3.01 (0.92--9.84)*RORC* gene rs9826CC7 (0.11)1 (0.01)**0.024** (3′ UTR)TT29 (0.45)45 (0.62)CT28 (0.44)27 (0.37)C allele42 (0.33)29 (0.20)**0.015**1.97 (1.14--3.41)T allele86 (0.67)117 (0.80)0.51 (0.29--0.88) rs1521177GG6 (0.10)1 (0.01)**0.017** (intron)TT29 (0.45)48 (0.66)GT29 (0.45)24 (0.33)G allele41 (0.32)26 (0.18)**0.006**2.18 (1.24--3.82)T allele87 (0.68)120 (0.82)0.46 (0.26--0.81)^a^Number of cases (frequency). *SNP* genotypes were determined using the iPLEX MassARRAY system (Sequenom Inc., USA), and allele frequencies and genotype distributions were calculated. Chi-square (χ^2^) and Fisher's exact tests were used to evaluate differences in SNP frequencies between HCV carriers and spontaneous resolvers. *P*-values, odds ratios, (*ORs*), and 95% confidence intervals, (*95% CIs*) were determined for association analysis. *P*-values (two-tailed) \< 0.05 were considered significant (bold)

Of the 22 remaining genes tested (excluding *IFNL3*), only SNPs rs9826 and rs1521177, located in non-coding regions of *RORC*, exhibited frequency differences between the "Resolved" and "Chronic" groups (rs9826: *P* = 0.024 for CC/TT/CT, *P* = 0.015 for C allele/T allele, OR = 1.97, 95% CI: 1.14-3.41; rs1521177: *P* = 0.017 for GG/TT/GT, *P* = 0.006 for G allele/T allele, OR = 2.18, 95% CI: 1.24-3.82)(Table [2](#Tab2){ref-type="table"}). The rs9826 TT and rs1521177 TT genotypes were associated with improved viral clearance. Overall, the primary cohort exhibited a similar distribution of *RORC* genotypes to Han Chinese nationality (Additional file [1](#MOESM1){ref-type="media"}: Table S3). The Hardy--Weinberg Equilibrium (HWE) test of three *IFNL3* SNPs and two *RORC* SNPs in the primary cohort were tested, and no SNPs with HWE violation were presented in the study (Additional file [1](#MOESM1){ref-type="media"}: Table S4).

In the present study, a minority of "Resolved" individuals were co-infected with HIV (HIV^pos^ resolved, *n* = 28) and very similar *IFNL3* (rs12979860, rs8099917, and rs12980275) and *RORC* (rs9826 and rs1521177) SNP genotype distributions were identified among HIV^neg^, HIV^pos^, and total resolved individuals (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). No association was observed between RORC SNPs (rs9826 and rs1521177) and HCV RNA levels in HIV-uninfected "Chronic" individuals (Additional file [1](#MOESM1){ref-type="media"}: Figure S2). In addition, we did not find any differences in genotypes and allele frequency distributions of *RORC* SNPs (rs9826 and rs1521177) between HIV^pos^ HCV carriers and HIV^pos^ HCV resolvers (Additional file [1](#MOESM1){ref-type="media"}: Table S5), and no associations between *RORC* SNPs and type of HCV genotypes (HCV 2a vs. HCV 1b) was found in HIV^neg^ HCV carriers (Additional file [1](#MOESM1){ref-type="media"}: Table S6).

Re-evaluation of RORC SNP associations with spontaneous HCV clearance in the IFNL3 favorable sub-cohort {#Sec8}
-------------------------------------------------------------------------------------------------------

In the *IFNL3* favorable sub-cohort, cases with unfavorable *IFNL3* genotypes in the "Chronic" (*n* = 10) and "Resolved" (*n* = 6) groups were excluded. Analysis of the sub-cohort indicated that significant differences between the two groups remained for rs1521177 (*P* = 0.040 for GG/TT/GT, *P* = 0.021 for G allele/T allele, OR = 2.00, 95% CI: 1.11-3.55), although no significant differences were identified for rs9826 (*P* = 0.092 for CC/TT/CT, *P* = 0.062 for C allele/T allele, OR = 1.74, 95% CI: 0.97-3.19) (Table [3](#Tab3){ref-type="table"}). These data suggested that SNP alleles in *RORC* had an independent effect on HCV viral clearance, which couldnot be explained by the distribution of *IFNL3* polymorphisms.Table 3Genotype and allele distributions of SNPs in the *RORC* gene in the *IFNL3* favorable sub-cohort^a^*RORC* SNPsChronic HCV^b^ (*n* = 54)Resolved HCV^b^ (*n* = 67)*P*-valueOR (95% CI)rs9826 CC5 (0.09)1 (0.01)0.092 TT26 (0.48)41 (0.61) CT23 (0.43)25 (0.37) C allele33 (0.31)27 (0.20)0.0621.74 (0.97--3.19) T allele75 (0.69)107 (0.80)0.57 (0.31--1.03)rs1521177 GG6 (0.11)1 (0.01)**0.040** TT26 (0.48)43 (0.64) GT22 (0.41)23 (0.34) G allele34 (0.31)25 (0.19)**0.021**2.00 (1.11--3.55) T allele74 (0.69)109 (0.81)0.50 (0.28--0.90)^a^Participants in the, *IFNL3* favorable sub-cohort were screened for, *IFNL3* genotypes (rs12979860CC/rs8099917TT/rs12980275AA)^b^Number of cases (frequency)*SNP* genotyping was conducted using the iPLEX MassARRAY system (Sequenom Inc., USA), and allele and genotype frequency distributions were calculated. Chi-square (χ^2^) and Fisher's exact tests were used to evaluate differences in, *SNP* frequencies between, *HCV* carriers and spontaneous resolvers. *P*-values, odds ratios, (*ORs*) and 95% confidence intervals, (*95% CIs*) were determined for association analysis. *P*-values (two-tailed) \< 0.05were considered significant (bold)

Analysis of the RORCrs9826/rs1521177 haplotype {#Sec9}
----------------------------------------------

Linkage disequilibrium tests for *RORC* and *IFNL3* SNPs in the primary cohort were shown in Additional file [1](#MOESM1){ref-type="media"}: Figure S3. The *RORC* SNPs, rs9826 and rs1521177, were determined to be in linkage disequilibrium (Primary cohort: D' = 0.831, r^2^ = 0.639; *IFNL3* favorable sub-cohort: D' = 0.812, r^2^ = 0.645) (Additional file [1](#MOESM1){ref-type="media"}: Table S7). Two main haplotypes were present in the primary cohort (rs9826-T/rs1521177-T: 62% vs. 79%, chronic vs. resolved; rs9826-C/rs1521177-G: 27% vs. 16%, chronic vs. resolved) and the *IFNL3* favorable sub-cohort (rs9826-T/rs1521177-T: 64% vs. 78%, chronic vs. resolved; rs9826-C/rs1521177-G: 26% vs. 17%, chronic vs. resolved). Overall, the presence of the rs9826-T/rs1521177-T haplotype was associated with a higher likelihood of spontaneous resolution in both the primary cohort (*P* = 0.0027, OR = 0.445, 95% CI: 0.26--0.76) and the *IFNL3* favorable sub-cohort (*P* = 0.0117, OR = 0.485, 95% CI:0.28--0.86). In addition, the frequency of the rs9826-C/rs1521177-G haplotype was significantly different between the chronic and resolved groups in the primary cohort (*P* = 0.0315, OR = 1.893, 95% CI:1.05--3.40), suggesting that individuals carrying this haplotype was difficult in spontaneous resolution of HCV infection (Table [4](#Tab4){ref-type="table"}).Table 4Common *RORC* SNP haplotypes (rs9826/rs1521177) and their association with spontaneous viral clearance in the primary cohort and *IFNL3* favorable sub-cohortChronic HCV^a^Resolved HCV^a^*P*-valueOR (95% CI)Primary cohort T/T0.620.79**0.0027**0.445(0.26--0.76) C/G0.270.16**0.0315**1.893(1.05--3.40)*IFNL3* favorable sub-cohort T/T0.640.78**0.0117**0.485(0.28--0.86) C/G0.260.170.10421.672(0.90--3.12)^a^Haplotype frequency. Chi-square (χ^2^) tests were used to evaluate differences in haplotype frequencies between, *HCV* carriers and spontaneous resolvers, using SHEsis software. Haplotypes with frequencies \< 0.05 (C/T, C/G, C/T, T/G) are not shown. *P*-values, odds ratios, (*ORs*) and 95% confidence intervals (*95% CIs*) were determined for association analysis. *P*-values (two-tailed) \< 0.05 were considered significant (bold)

Discussion {#Sec10}
==========

Genetic polymorphisms of innate immunity-related genes were reported to be associated with HCV clearance \[[@CR28], [@CR29]\]. Specially, SNPs of the *IFNL3* (IL-28B) have shown strong association with spontaneous clearance of HCV and with the response to anti-HCV therapy \[[@CR30]--[@CR33]\]. Another important correlation of HCV spontaneously viral clearance was a robust and sustained HCV-specific T cell response. Cumulative studies indicated that HLA-associated viral polymorphisms were closely correlated with immune recognition of T cells to virus (both HIV and HCV) \[[@CR34]--[@CR37]\].

Exploration of adaptive immune factors involved in spontaneous clearance of viral infection will help to understand HCV pathogenesis. Besides *IFNL* genotypes, HCV-specific T cells are typically detectable 5--9 weeks after acute infection \[[@CR38], [@CR39]\]. Recently, Grebely et al. reported that the median time for acute HCV clearance among 173 spontaneous resolvers undergoing follow-up observation was 16.5 weeks \[[@CR9]\], indicating that a strong, broad, and persistent HCV-specific adaptive immune response is required during acute infection for viral clearance \[[@CR40]\].

The role of Th17 responses in HCV pathogenesis is intriguing but not well characterized. Numerous studies have focused on its destructive potentials, since they could aggravate the severity of fibrosis and intrahepatic inflammatory status \[[@CR22], [@CR41], [@CR42]\]. However, some studies have also reported a role for Th17 responses in spontaneous HCV clearance. Kared et al. reported that the differentiation of IL-17A-producing CD4+ T cells was correlated with prognosis of infection \[[@CR26]\]. In addition, the concentration of plasma IL-17A was significantly higher in the acute phase of HCV infection in patients with self-limiting infection than in those with chronically evolving hepatitis \[[@CR26]\]. Moreover, Seetharam et al. described a transient IL-17 response followed by a subsequent reactivation of Th1 responses, resulting to spontaneous recovery in a liver transplant recipient with recurrent hepatitis C \[[@CR25]\]. It is possible that Th17 responses in HCV-associated disorders may act as a double-edged sword, playing different roles in different disease courses.

In this study, a number of the HCV resolvers had a background of HIV infection, which could be primarily ascribed to historical contaminated commercial blood donations in the late 1990s. As HCV is more efficiently transmitted through blood contamination or infected needles than HIV, self-limiting acute HCV infection in these individuals may usually precede, or be coincident with, HIV infection \[[@CR6], [@CR43], [@CR44]\]. Regardless of whether spontaneous recovery from HCV occurred before or after HIV infection, it remains conceivable that genetic immune characteristics of these individuals could be associated with spontaneous HCV eradication. By contrast, we excluded chronically HIV/HCV-co-infected patients from the study, due to the possibility that some HIV-co-infected individuals who could clear HCV spontaneously in the absence of HIV became chronic HCV carriers. In addition, all the participants in this study came from the same village and shared similar characteristics of viral contamination mode, daily diet, surrounding environment, ethnicity, and income level, which strengthed the comparison of genetic immune factors between HCV carriers and resolvers. Among the two *RORC* SNPs (rs9826 and rs1521177) identified in this study, the rs9826 polymorphism was associated with severity of rheumatoid arthritis in the Polish population \[[@CR45]\]. Further functional studies to explore the associations between *RORC* SNPs genotypes and Th17 responses, as well as Th17 responses and viral clearance, should be performed in the future.

Our cohort design precluded the influence factors of ethnicity, gender and IFNL-3. However, the sample size of our cohort was still limited, and future larger-scale queues were needed for better verification of our conclusion. In addition, the *RORC* SNPs rs9826-T and rs1521177-T were validated in only Chinese Han population in this study. The adaptation of these SNPs in other ethnic and national populations needs to be further analyzed.

Conclusions {#Sec11}
===========

The present study determined that polymorphisms in human Th17-related *RORC* gene were associated with differing natural prognosis for Chinese Han females with HCV infection. The most common *RORC* haplotype in this cohort, rs9826-T/rs1521177-T, was favorable for spontaneous clearance of HCV infection.

Additional file
===============

 {#Sec12}

Additional file 1:**Figure S1.** Comparison of distributions of *IFNL3* and *RORC* SNP genotypes among HIVneg, HIVpos, and total resolved individuals. (**a**) Distribution of genotypes (%) of three *IFNL3* SNPs (rs12979860, rs8099917, and rs12980275). (**b**) Distribution of genotypes (%) of two *RORC* SNPs (rs9826, and rs1521177). Chi-square (χ2) and Fisher's exact tests were used to evaluate the differences in SNP distributions between two groups. *P*-values (two-tailed) \< 0.05 were considered significant (n.s., not significant). **Figure S2.** HCV viral load levels of *RORC* SNP genotypes (rs9826, rs1521177) among HIV^neg^ HCV carriers of the primary cohort. **Figure S3.** Linkage disequilibrium tests for RORC SNPs (rs9826 and rs1521177) and *IFNL3* SNPs (rs12979860, rs8099917 and rs12980275) in the primary cohort (**a**) D' value. (**b**) r^2^ value. **Table S1.** Allele frequencies of *IFNL3* gene SNPs in different populations. **Table S2.** Allele, genotype, and carrier frequencies and percentages of tested SNPs in the primary cohort. **Table S3.** *RORC* gene SNP allele frequencies in different populations. **Table S4.** The Hardy--Weinberg Equilibrium (HWE) test of all SNPs in the whole study population. **Table S5.** Genotype and allele frequency distributions of *RORC* SNPs in HIV^pos^ group. **Table S6.** Genotype and allele frequency distributions of *RORC* SNPs in HIV^neg^ HCV carriers of the primary cohort. **Table S7.** Linkage disequilibrium tests for *RORC* rs9826/rs1521177 in the primary cohort and the *IFNL3* favorable sub-cohort. (DOC 1671 kb)
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